Hepatocellular carcinoma is one of the leading causes of cancer-related death worldwide, largely due to its high rate of ...

NEW YORK (Medscape Wire) May 22 -- Chemoembolization should be the standard approach in selected patients with unresectable hepatocellular carcinoma, based on improved survival in a randomized trial ...

Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial ...

Combination therapy with lenvatinib and anti-PD-1 antibodies for unresectable or advanced hepatocellular carcinoma: A real-world study. This is an ASCO Meeting Abstract from the 2020 ASCO Annual ...

Hepatocellular carcinoma (HCC) poses a substantial health burden globally, with liver cancer being the fourth most common cause of cancer-related mortality worldwide. In China, where the incidence of ...

Please provide your email address to receive an email when new articles are posted on . Hepatocellular carcinoma accounts for approximately 90% of all primary liver cancer cases, according to Zhen-Wei ...

Regional chemotherapy via a tumour-feeding artery achieves higher drug exposure at the target site than with corresponding systemic exposure and, therefore, has the possibility of generating higher ...

May 20, 2009 —The Journal of the American Medical Association (JAMA) has retracted an article that it published a year ago on the use of chemoembolization in liver cancer. The article, by Bao-quan ...

The latest published report namely Global Transarterial Chemoembolization (TACE) Market Size, Share, Growth, Industry Trends and Forecast to 2028 added by Data Bridge Market Research contains point by ...

Introduction: In patients with inoperable intrahepatic cholangiocarcinoma (ICC), both conventional transarterial chemoembolization (cTACE) and drug-eluting bead TACE (DEB-TACE) can be employed as ...